Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Drug Interactions
Conditions
Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering
Trial Timeline
Apr 3, 2025 → Dec 31, 2026
NCT ID
NCT06865885About Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL is a approved stage product being developed by Novartis for Drug Interactions. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06865885. Target conditions include Drug Interactions, Primary Prevention, Cardiometabolic Syndrome.
What happened to similar drugs?
7 of 14 similar drugs in Drug Interactions were approved
Approved (7) Terminated (3) Active (5)
✅Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDHaisco Pharmaceutical GroupApproved
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06865885 | Approved | Recruiting |
Competing Products
20 competing products in Drug Interactions